CA3184089A1 - Compounds for drug delivery across blood-brain barrier - Google Patents
Compounds for drug delivery across blood-brain barrierInfo
- Publication number
- CA3184089A1 CA3184089A1 CA3184089A CA3184089A CA3184089A1 CA 3184089 A1 CA3184089 A1 CA 3184089A1 CA 3184089 A CA3184089 A CA 3184089A CA 3184089 A CA3184089 A CA 3184089A CA 3184089 A1 CA3184089 A1 CA 3184089A1
- Authority
- CA
- Canada
- Prior art keywords
- beads
- cells
- brain
- compounds
- trbp6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047440P | 2020-07-02 | 2020-07-02 | |
| US63/047,440 | 2020-07-02 | ||
| PCT/US2021/038408 WO2022005807A1 (en) | 2020-07-02 | 2021-06-22 | Compounds for drug delivery across blood-brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3184089A1 true CA3184089A1 (en) | 2022-01-06 |
Family
ID=77317394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3184089A Pending CA3184089A1 (en) | 2020-07-02 | 2021-06-22 | Compounds for drug delivery across blood-brain barrier |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230257420A1 (https=) |
| EP (1) | EP4175715A1 (https=) |
| JP (1) | JP2023532736A (https=) |
| CA (1) | CA3184089A1 (https=) |
| WO (1) | WO2022005807A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002359679B2 (en) * | 2001-12-11 | 2009-01-08 | Cellgate, Inc. | Guanidinium transport reagents and conjugates |
| US20180156826A1 (en) * | 2015-06-08 | 2018-06-07 | The Board Of Regents Of The University Of Texas Sy Stem | Compositions and methods for diagnosis of autism spectrum disorder |
| US10849875B2 (en) * | 2015-07-23 | 2020-12-01 | University Of Houston System | Cancer specific lipid targeted peptidomimetics |
-
2021
- 2021-06-22 JP JP2022581583A patent/JP2023532736A/ja active Pending
- 2021-06-22 US US18/011,649 patent/US20230257420A1/en active Pending
- 2021-06-22 WO PCT/US2021/038408 patent/WO2022005807A1/en not_active Ceased
- 2021-06-22 EP EP21754858.5A patent/EP4175715A1/en active Pending
- 2021-06-22 CA CA3184089A patent/CA3184089A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4175715A1 (en) | 2023-05-10 |
| JP2023532736A (ja) | 2023-07-31 |
| US20230257420A1 (en) | 2023-08-17 |
| WO2022005807A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6495663B1 (en) | Method and composition for enhancing transport across biological membranes | |
| EP2505211B1 (en) | Molecules for targeting compounds to various selected organs or tissues | |
| US20080070843A1 (en) | Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics | |
| BRPI0620806B1 (pt) | A complex and composition comprising a peptide and a charge molecule, and use of said composition | |
| US20240165245A1 (en) | Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same | |
| CN102177174B (zh) | 用于靶向凋亡细胞的肽及其用途 | |
| CN113549129B (zh) | 一种d-构型抗肿瘤肽及其制备方法和应用 | |
| KR100968839B1 (ko) | 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도 | |
| CN113604214A (zh) | 一种高稳定性溶瘤肽荧光探针及其制备方法和应用 | |
| Shukla et al. | A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells | |
| JP2025514805A (ja) | 化合物及び使用 | |
| JP4603364B2 (ja) | ペプチドギャップ結合モジュレーター | |
| US20230257420A1 (en) | Compounds for drug delivery across blood-brain barrier | |
| EP1879911B1 (en) | Dye conjugates of template-fixed peptidomimetics | |
| WO2025189832A1 (zh) | 一种抗肿瘤化合物及其制备方法和应用 | |
| US20240083949A1 (en) | Cell penetrating peptide compositions and methods thereof | |
| CN100365014C (zh) | 肿瘤靶向剂及其应用 | |
| EP4714964A1 (en) | Peptide fragment and use thereof | |
| US20110237499A1 (en) | Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses | |
| EP4714963A1 (en) | Peptide fragment and use thereof | |
| EP4582435A1 (en) | Carrier peptide fragment and use thereof | |
| RU2377247C2 (ru) | Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты) | |
| RU2820346C2 (ru) | Билигандный конъюгат лекарственного средства и его применение | |
| CN101027316A (zh) | 肿瘤靶向剂及其应用 | |
| US20030207400A1 (en) | Vectors for dna delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250613 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250613 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250618 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250618 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250826 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250826 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250827 |